LY2109761, the first discovered TβRI and TβRII dual kinase inhibitor [401], exhibiting high potency and specificity compared to other ALK5 inhibitors and oral bioavailability, was used successfully in an orthoptic murine model of PC. The gene discussed is TGFBR1; the disease is pachyonychia congenita.